Publikationer baserade på IMSE-material

Publikationer 2019

Retinal nerve fiber layer thickness associates with cognitive impairment and physical disability in multiple sclerosis.
Birkeldh U, Manouchehrinia A, Hietala MA, Hillert J, Olsson T, Piehl F, et al
Mult Scler Relat Disord 2019 Sep;36():101414

Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility.
Science 2019 09;365(6460):

Comparative effectiveness of dimethyl fumarate as the initial and secondary treatment for MS.
Granqvist M, Burman J, Gunnarsson M, Lycke J, Nilsson P, Olsson T, et al
Mult. Scler. 2019 Aug;():1352458519866600

Cognitive function is a major determinant of income among multiple sclerosis patients in Sweden acting independently from physical disability.
Kavaliunas A, Danylaite Karrenbauer V, Gyllensten H, Manouchehrinia A, Glaser A, Olsson T, et al
Mult. Scler. 2019 01;25(1):104-112

Cognitive function predicts work disability among multiple sclerosis patients.
Kavaliunas A, Tinghög P, Friberg E, Olsson T, Alexanderson K, Hillert J, et al
Mult Scler J Exp Transl Clin ;5(1):2055217318822134

Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies.
Luna G, Alping P, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M, et al
JAMA Neurol 2019 Oct;():

Molecular mimicry between Anoctamin 2 and Epstein-Barr virus nuclear antigen 1 associates with multiple sclerosis risk.
Tengvall K, Huang J, Hellström C, Kammer P, Biström M, Ayoglu B, et al
Proc. Natl. Acad. Sci. U.S.A. 2019 Aug;116(34):16955-16960

Publikationer 2018

Multiple sclerosis treatment effects on plasma cytokine receptor levels.
Bedri SK, Fink K, Manouchehrinia A, Lundström W, Kockum I, Olsson T, et al
Clin. Immunol. 2018 02;187():15-25

Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk.,
Cell 2018 11;175(6):1679-1687.e7

DNA methylation as a mediator of HLA-DRB1*15:01 and a protective variant in multiple sclerosis.
Kular L, Liu Y, Ruhrmann S, Zheleznyakova G, Marabita F, Gomez-Cabrero D, et al
Nat Commun 2018 06;9(1):2397

Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod.
Piehl F, Kockum I, Khademi M, Blennow K, Lycke J, Zetterberg H, et al
Mult. Scler. 2018 07;24(8):1046-1054

Publikationer 2017

Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis.
Novakova L, Axelsson M, Khademi M, Zetterberg H, Blennow K, Malmeström C, et al
J. Neurochem. 2017 04;141(2):296-304

Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis.
Novakova L, Axelsson M, Khademi M, Zetterberg H, Blennow K, Malmeström C, et al
Mult. Scler. 2017 01;23(1):62-71

Fourteen sequence variants that associate with multiple sclerosis discovered by meta-analysis informed by genetic correlations.
Olafsson S, Stridh P, Bos SD, Ingason A, Euesden J, Sulem P, et al
NPJ Genom Med 2017 ;2():24

Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis.
Olsson T, Barcellos LF, Alfredsson L
Nat Rev Neurol 2017 Jan;13(1):25-36

Publikationer 2016

[New techniques can radically change health care].
Benson M, Olsson T
Lakartidningen 2016 Feb;113():

NR1H3 p.Arg415Gln Is Not Associated to Multiple Sclerosis Risk.
Neuron 2016 Oct;92(2):333-335

Comparative analysis of first-year fingolimod and natalizumab drug discontinuation among Swedish patients with multiple sclerosis.
Frisell T, Forsberg L, Nordin N, Kiesel C, Alfredsson L, Askling J, et al
Mult. Scler. 2016 Jan;22(1):85-93

Environmental factors and their interactions with risk genotypes in MS susceptibility.
Hedström AK, Alfredsson L, Olsson T
Curr. Opin. Neurol. 2016 06;29(3):293-8

Publikationer 2015

Age-dependent effects on the treatment response of natalizumab in MS patients.
Matell H, Lycke J, Svenningsson A, Holmén C, Khademi M, Hillert J, et al
Mult. Scler. 2015 Jan;21(1):48-56

Class II HLA interactions modulate genetic risk for multiple sclerosis.
Moutsianas L, Jostins L, Beecham AH, Dilthey AT, Xifara DK, Ban M, et al
Nat. Genet. 2015 Oct;47(10):1107-1113

PML: The Dark Side of Immunotherapy in Multiple Sclerosis.
Warnke C, Olsson T, Hartung HP
Trends Pharmacol. Sci. 2015 Dec;36(12):799-801

Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF.
Warnke C, Stettner M, Lehmensiek V, Dehmel T, Mausberg AK, von Geldern G, et al
Mult. Scler. 2015 Jul;21(8):1036-44

Publikationer 2014

Variability in the CIITA gene interacts with HLA in multiple sclerosis.
Gyllenberg A, Piehl F, Alfredsson L, Hillert J, Bomfim IL, Padyukov L, et al
Genes Immun. ;15(3):162-7

Smoking and risk of treatment-induced neutralizing antibodies to interferon β-1a.
Hedström AK, Ryner M, Fink K, Fogdell-Hahn A, Alfredsson L, Olsson T, et al
Mult. Scler. 2014 Apr;20(4):445-50

JC polyomavirus infection is strongly controlled by human leucocyte antigen class II variants.
Sundqvist E, Buck D, Warnke C, Albrecht E, Gieger C, Khademi M, et al
PLoS Pathog. 2014 Apr;10(4):e1004084

Initial lymphocyte count and low BMI may affect fingolimod-induced lymphopenia.
Warnke C, Dehmel T, Ramanujam R, Holmen C, Nordin N, Wolfram K, et al
Neurology 2014 Dec;83(23):2153-7

Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy.
Warnke C, von Geldern G, Markwerth P, Dehmel T, Hoepner R, Gold R, et al
Ann. Neurol. 2014 Dec;76(6):792-801

Publikationer 2013

Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis.
Beecham AH, Patsopoulos NA, Xifara DK, Davis MF, Kemppinen A, et al
Nat. Genet. 2013 Nov;45(11):1353-60

Network-based multiple sclerosis pathway analysis with GWAS data from 15,000 cases and 30,000 controls.
Am. J. Hum. Genet. 2013 Jun;92(6):854-65

Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort.
Olsson T, Achiron A, Alfredsson L, Berger T, Brassat D, Chan A, et al
Mult. Scler. 2013 Oct;19(11):1533-8

Changes to anti-JCV antibody levels in a Swedish national MS cohort.
Warnke C, Ramanujam R, Plavina T, Bergström T, Goelz S, Subramanyam M, et al
J. Neurol. Neurosurg. Psychiatry 2013 Nov;84(11):1199-205

Publikationer 2012

Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab.
Sørensen PS, Bertolotto A, Edan G, Giovannoni G, Gold R, Havrdova E, et al
Mult. Scler. 2012 Feb;18(2):143-52

Publikationer 2011

Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab.
Gunnarsson M, Malmeström C, Axelsson M, Sundström P, Dahle C, Vrethem M, et al
Ann. Neurol. 2011 Jan;69(1):83-9

Functional energetics of CD4+-cellular immunity in monoclonal antibody-associated progressive multifocal leukoencephalopathy in autoimmune disorders.
Haghikia A, Perrech M, Pula B, Ruhrmann S, Potthoff A, Brockmeyer NH, et al
PLoS ONE 2011 Apr;6(4):e18506

A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis.
Holmén C, Piehl F, Hillert J, Fogdell-Hahn A, Lundkvist M, Karlberg E, et al
Mult. Scler. 2011 Jun;17(6):708-19

Swedish natalizumab (Tysabri) multiple sclerosis surveillance study.
Piehl F, Holmén C, Hillert J, Olsson T
Neurol. Sci. 2011 Jan;31 Suppl 3():289-93

Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy.
Vermersch P, Kappos L, Gold R, Foley JF, Olsson T, Cadavid D, et al
Neurology 2011 May;76(20):1697-704

Publikationer 2009

Progressive multifocal leukoencephalopathy after natalizumab monotherapy.
Lindå H, von Heijne A, Major EO, Ryschkewitsch C, Berg J, Olsson T, et al
N. Engl. J. Med. 2009 Sep;361(11):1081-7